Capricor Therapeutics, Inc.'s (CAPR): Analysts See 489% Upside Potential

By Yahoo! Finance   |   1 month ago
Capricor Therapeutics, Inc.'s (CAPR): Analysts See 489% Upside Potential

Capricor Therapeutics (NASDAQ:CAPR) focuses on developing cell and exosome-based therapies for genetic disorders like Duchenne muscular dystrophy.

Read More

Did you find this insightful?